...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of psychiatric research >Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
【24h】

Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.

机译：多巴胺D2受体占有率，临床反应与血浆和脑脊液中药物和单胺代谢产物水平之间的关系。喹硫平治疗首发精神分裂症患者的初步研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Combining measurements of the monoamine metabolites in the cerebrospinal fluid (CSF) and neuroimaging can increase efficiency of drug discovery for treatment of brain disorders. To address this question, we examined five drug-naive patients suffering from schizophrenic disorder. Patients were assessed clinically, using the Positive and Negative Syndrome Scale (PANSS): at baseline and then at weekly intervals. Plasma and CSF levels of quetiapine and norquetiapine as well CSF 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxyindole-acetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) were obtained at baseline and again after at least a 4 week medication trail with 600 mg/day quetiapine. CSF monoamine metabolites levels were compared with dopamine D(2) receptor occupancy (DA-D(2)) using [(18)F]fallypride and positron emission tomography (PET). Quetiapine produced preferential occupancy of parietal cortex vs. putamenal DA-D(2), 41.4% (p<0.05, corrected for multiple comparisons). DA-D(2) receptor occupancies in the occipital and parietal cortex were correlated with CSF quetiapine and norquetiapine levels (p<0.01 and p<0.05, respectively). CSF monoamine metabolites were significantly increased after treatment and correlated with regional receptor occupancies in the putamen [DOPAC: (p<0.01) and HVA: (p<0.05)], caudate nucleus [HVA: (p<0.01)], thalamus [MHPG: (p<0.05)] and in the temporal cortex [HVA: (p<0.05) and 5-HIAA: (p<0.05)]. This suggests that CSF monoamine metabolites levels reflect the effects of quetiapine treatment on neurotransmitters in vivo and indicates that monitoring plasma and CSF quetiapine and norquetiapine levels may be of clinical relevance.
机译：脑脊液（CSF）和神经影像学中单胺代谢物的组合测量可提高发现药物治疗脑部疾病的效率。为了解决这个问题，我们检查了5位未接受过药物治疗的精神分裂症患者。使用阳性和阴性综合征量表（PANSS）对患者进行临床评估：基线时，然后每周一次。喹硫平和去甲喹诺平以及CSF 3,4-二羟基苯基乙酸（DOPAC），高香草酸（HVA），5-羟基吲哚-乙酸（5-HIAA）和3-甲氧基-4-羟基苯基乙二醇（MHPG）的血浆和CSF水平为在基线时以及在服用至少600 mg /天的喹硫平至少4周后再次获得。脑脊液单胺代谢物水平与多巴胺D（2）受体占有率（DA-D（2））使用[（18F）Fallypride和正电子发射断层扫描（PET）比较。喹硫平产生的顶叶皮层相对于普达美DA-D（2）的优先占有率为41.4％（p <0.05，经多次比较校正）。 DA-D（2）受体在枕叶和顶叶皮层的占有率与CSF喹硫平和降血平的水平相关（分别为p <0.01和p <0.05）。治疗后脑脊液单胺代谢物显着增加，并与壳核中的区域受体占有率[DOPAC：（p <0.01）和HVA：（p <0.05）]，尾状核[HVA：（p <0.01）]，丘脑[MHPG] ：（p ＜0.05）]和颞皮质[HVA：（p ＜0.05）和5-HIAA：（p ＜0.05）]。这表明脑脊液单胺代谢产物水平反映了喹硫平治疗对体内神经递质的影响，并表明监测血浆和脑脊液喹硫平和降血平的水平可能与临床有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号